Agoracom Blog Home

Posts Tagged ‘CSE’

#Edtech Startups Look For Permanence Beyond The #Covid19 Lockdown Boom – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 12:07 PM on Wednesday, May 20th, 2020

SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. betterU / Ottolearn launch FREE COVID-19 mobile resource toolkit to fight the global crisis – Click here for more information.

Edtech Startups Look For Permanence Beyond The Covid-19 Lockdown Boom

  • Since the lockdown, Indian edtech companies have reported major spikes in their user registrations and engagement
  • Upskilling has emerged as a growing trend among Indian adults as the lockdown increased downtime for employees
  • Edtech startups believe that online learning will be largely immune to the post-lockdown decline in digital adoption

By: Yatti Soni

It’s no surprise that the countrywide school and college shutdown has brought edtech to the fore. While earlier, it felt like a luxury, online learning is pretty much the only option now for students, teachers and schools. Right from the very first week of the lockdown in India, edtech platforms moved to capitalise on the growth wave and it resulted in an unprecedented spike in user registrations and time spent on online learning platforms. 

According to SimilarWeb, based on a study of 35 top online learning platforms, the edtech segment saw a 26% increase in user visits between April 2019 to March 2020, as compared to April 2018 – March 2019. Further, the first 28 days of lockdown in India edtech segment saw 128.8 Mn visits (on average, 4.6Mn daily visits) as compared to 102.2 Mn average visits between April 2019 – Feb 2020.

Read More: https://inc42.com/features/edtech-startups-look-for-permanence-beyond-the-covid-19-lockdown-boom/

Empower $CBDT.ca Signs Term Sheet to Acquire Interest in Dosed Movie and Launches New #Psychedelics Company Dosed Wellness Ltd. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:53 AM on Wednesday, May 20th, 2020
  • Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie,
  • launches Dosed Wellness, a psychedelics brand,
  • launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand

VANCOUVER BC / May 20, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce it has entered into a non-binding term sheet with Golden Teacher Films Inc. (“Golden“) to acquire a 10% interest in certain royalty rights, intellectual property rights and interest in Dosed Movie (“DOSED”), an award-wining documentary film about treating anxiety, depression and addiction with psychedelic medicine.

Under the terms of the agreement, the Company intends to issue $75,000.00 CAD of common shares in the capital of Empower (each, a “Share”) plus an aggregate payment of $25,000.00 CAD to the Vendors at the Closing. Further, the principals of Golden, Tyler Chandler and Nicholas Meyers will be offered consulting contracts to join the management team of Dosed Wellness Ltd.

The Company also announces the launch of a dedicated psychedelics division Dosed Wellness Ltd. (“Dosed Wellness”) and a new dedicated website www.dosedwellness.com that will leverage the operating assets of Empower. Dosed Wellness is uniquely positioned as an early mover in the psychedelics space with a network of physicians and clinics, advanced research opportunities, telehealth capabilities, and a growing base of over 165,000 patients.

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

“Widespread legalization of psilocybin and psychedelics is inevitable, as clinical research is showing these compounds are uniquely useful for treating mental illness and addiction.” said Tyler Chandler, Director of DOSED. “Since billions of people worldwide suffer from these conditions, we need to establish infrastructure and patient-care competencies to serve this population as soon as the law allows. We’re thrilled to align with Empower Clinics, which has the strategic vision, existing client base and clinic network to continue to lead the plant-based medicine industry.”

“The opportunity to partner with DOSED to help bring down stigmas and advance the science of psychedelic treatment options is a meaningful step forward to vastly improving the mental wellness outcome for millions of people around the world.” said Steven McAuley, Chairman and CEO of Empower. “Now, with the additions of Tyler and Nick on our new management team, we will leverage their substantial psychedelics experience and network to take full advantage of Empowers’ clinic infrastructure, technology and access to patients.”

According to the World Health Organization depression is already the leading cause of disability worldwide (more than 322 million people suffer from depression) and is a major contributor to the overall global burden of disease.

Both MDMA and psilocybin, combined with a course of therapy, have received Breakthrough Therapy Designation (BTD) from the FDA in the US, which means both are one step closer to licensing approval.

“Our team is well connected in the psychedelic space and our expertise on the media side will help elevate the Empower brand. We’re also excited that Empower Clinics is acquiring an interest in DOSED, as their promotion of the film will help educate millions of people about the opportunities inherent in psychedelic medicine.” said Nicholas Meyers, Producer of DOSED. “When people see Adrianne’s inspiring and eye-opening journey in DOSED, they’ll want to know how to access these treatments, which is precisely the problem Empower Clinics is positioned to solve as we move towards clinical trials and legalization.”

Psychedelic medicines derived from or inspired by plants and fungi found in nature have the potential to redefine how mental health conditions could be treated over the course of the next decade. Prohibition Partners Psych: The Psychedelics as Medicine Report March 2020

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

About Dosed Movie

After many years of prescription medications failing her, a suicidal woman turns to underground healers to try and overcome her depression, anxiety, and opioid addiction with illegal psychedelic medicine such as magic mushrooms and iboga. Adrianne’s first dose of psilocybin mushrooms catapulted her into an unexpected world of healing where plant medicines are redefining our understanding of mental health and addiction. DOSED is directed and produced by Tyler Chandler and Nicholas Meyers is producer and director of photography. Visit www.dosedmovie.com to rent or own DOSED.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Mota Schedules Conference Call to Discuss Recent Announcements $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:20 PM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 19, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ)(OTC:PEMTF) (the “Company) a direct to consumer provider of a wide range of CBD products globally, is pleased to announce it will be hosting an investor conference call on Wednesday, May 20, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss recent announcements.

The call will be held on May 20, at 1:15 pm Pacific Time.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: 1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com.

Mota Ventures $MOTA.ca Announces Completion Of Audit For Nature’s Exclusive Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:31 AM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC, CANADA / ACCESSWIRE / May 19, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce completion of an audit of the financial results of its Nature’s Exclusive brand through the twelve-months ended December 31, 2019.

  • 2019 audited financial results:
  • Revenue of Cdn$29,034,000
  • Associated expenses of Cdn$25,530,000
  • Net income of Cdn $3,505,000

“Completion of the 2019 audit is a culmination of an extensive team effort, and represents a significant milestone in the validation of our eCommerce business. The 2019 figures, where we achieved over 12% net income, provides us with a benchmark from which to measure our success in the 2020 fiscal year as we continue to build on the strong results generated by Unified,” noted Ryan Hoggan, Chief Executive Officer of the Company.

Throughout the 2019 calendar year, the Nature’s Exclusive brand was operated as a separate business segment of Unified Funding, LLC (“Unified“). The Company completed the acquisition of the brand, and the associated business line, on January 17, 2020. The audit was completed on carve-out financial statements of Unified, which present the standalone financial results of the brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada average annual exchange rate of US$1.00:Cdn$1.3269 for 2019.

The Company also announces that it has reached an agreement with Unified to amend the thresholds necessary for Unified to earn a bonus based on the financial results generated by the Nature’s Exclusive brand in the 2020 calendar year. Unified is entitled to earn a bonus payment based on the terms of the original transaction in which Mota acquired control of the brand, and the associated business line.

Under the terms of the amendment, Unified will continue to be entitled to a one-time bonus payment (the “Bonus Payment“) based on the revenue and profitability of Nature’s Exclusive in the 2020 calendar year. The Bonus Payment will be: (i) US$5,000,000, in the event gross revenue exceeds US$40,000,000 with a profit margin of at least ten percent; (ii) US$10,000,000, in the event gross revenue exceeds US$45,000,000 with a profit margin of at least ten percent; or (iii) US$15,000,000, in the event gross revenue exceeds US$50,000,000. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“) based on an exchange rate of US$1.00 to C$1.30 and the greater of: (i) C$0.80; and (ii) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the last trading day of 2020. Any Bonus Shares issuable by the Company will be subject to the terms of a thirty-six month time release pooling arrangement, with applicable release dates calculated from the date of issuance of the Bonus Shares.

For further information regarding the Bonus Payment, and the acquisition of Nature’s Exclusive, readers are encouraged to review the Company’s news release of January 17, 2020.

“Revising the 2020 performance bonus will help to align our interests with Unified, and ensure they remain incentivized in the development of Nature’s Exclusive in the context of the current market. The brand has demonstrated strong financial results through 2020 to date, in spite of economic volatility and we look forward to continued success leading into the second half of 2020,” commented Ryan Hoggan, Chief Executive Officer of the Company.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Datametrex $DM.ca Adds Pharmacologist Alex MacGregor to the Medical Advisory Board

Posted by AGORACOM-JC at 10:04 AM on Tuesday, May 19th, 2020
  • President and Dean of the Toronto Institute of Pharmaceutical Technology and Clinical Pharmacologist, Dr. Alexander MacGregor, Ph.D., a, has consented to join the Company’s Medical Advisory Board.
  • Company is also in discussion with Transpharm Canada Inc. the parent company of Toronto Institute of Pharmaceutical Technology to provide lab testing services using there fully compliant Health Canada licensed Good Manufacturing Practice manufacturing and testing facility located in Toronto, ON, Canada

TORONTO, May 19, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that President and Dean of the Toronto Institute of Pharmaceutical Technology (“TIPT”) and Clinical Pharmacologist, Dr. Alexander MacGregor, Ph.D., a, has consented to join the Company’s Medical Advisory Board.

The Company is also in discussion with Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology to provide lab testing services using their fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility located in Toronto, ON, Canada. Having a mass testing partner will be a key growth driver for the Company and will be working to solidify an agreement on this prospective joint project.

Datametrex is extremely pleased to have an medical patent holder and pharmacologist with the experience and abilities of Dr. MacGregor join its Medical Advisory Board,” said Marshall Gunter, CEO of Datametrex. “Alexander will be an excellent source of advice as the Company advances a key part of covid-19 with lab capacity and his and his teams pharmacology expertise. We welcome Dr. MacGregor and look forward to his valued contribution as the newest member of our team.”

Dr. Alexander MacGregor stated, “I am very pleased to join the Company’s medical advisory board. With this unprecedented pandemic terribly affecting people worldwide and has temporarily changed the way the world operates, I am pleased to be assisting Datametrex with my teams expertise in lab testing on the front lines and assisting developing a plan to meet the enormous demand coming in COVID-19 testing and working on lowering the curve during this outbreak.”

About Dr. Alexander MacGregor

A leader in the fields of pharmaceutical technology, research, and training, Dr. MacGregor has served as the President and Dean of Faculty of the Toronto Institute of Pharmaceutical Technology (TIPT®) since 1992.

The holder of several scientific patents, Dr. MacGregor currently oversees clinical testing trials of several drugs in the areas of cholesterol lowering, diabetes, anti-infective, post-operative pain, epilepsy, and congestive heart failure.

Dr. MacGregor obtained his Ph.D. in clinical pharmacology from the University of London Postgraduate Medical School after earning B.Sc. (Honors) in Medical Biochemistry from the Cardif University in Wales. In 1997, Dr. MacGregor completed a Master-Class Certification Program in Pharmaceutical Technology from the European Continuing Education College at the University of Liverpool.

In 1990, Dr. MacGregor moved to Canada to assume the role of managing director of Transpharm International UK Ltd., a scientific enterprise specializing in clinical testing and pharmaceutical drug licensing. Throughout the decade, Dr. MacGregor functioned as a consultant to major pharmaceutical industries in Europe, Asia, and North America.

Dr. MacGregor currently divides his time between TIPT, one of North America’s leading postgraduate pharmaceutical and research organizations, and ORx Pharmaceutical Corporation, where he serves as chairman and Chief Scientific Officer. In the latter capacity, Dr. MacGregor designs and develops clinical delivery methods of therapeutic compounds.

At TIPT, Dr. MacGregor runs a highly regarded training program in pharmaceutical sciences and technology. More than 7,500 successful TIPT graduates operate in all areas of the pharmaceutical industry including quality control analysis, regulatory affairs administration, clinical quality control, and clinical data review.

An active humanitarian within the African-Canadian community, Dr. MacGregor supports such organizations as the Canadian Association of Black Lawyers (CABL) and the Association of Black Law Enforcers (ABLE). Dr. MacGregor also donates generously to charities such as the United Way and the Nelson Mandela Children’s fund.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

North Bud Farms $NBUD.ca Announces Proposed Terms for Non-Brokered Private Placement of Units $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, May 19th, 2020
  • Intends to complete a non-brokered private placement of units at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million
  • Proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations.

TORONTO, May 19, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce that it intends to complete a non-brokered private placement of units (each a “Unit”) at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million (the “Offering”).

Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share (a “Warrant Share”) for a period of 24 months following the Closing Date (as defined below) at an exercise price equal to: (i) $0.075 if the Warrant is exercised within 12 months of the Closing Date, or (ii) $0.10 if the Warrant is exercised at any other time prior to expiry.

The Company may pay a cash fee or issue compensation securities to certain eligible finders in connection with the proceeds received by the Company from the sale of Units to subscribers introduced to the Company by such eligible finders.

The proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations. Management believes that securing a 12-month cash runway is the most prudent step in attempting to secure the long-term viability of the Company. Failure to meet these capital requirements could force management to proceed with secondary options that may preserve less long-term value for shareholders. Subscription receipts will be held in escrow and released upon the filing of the Company’s 2019 financial statements.  The Offering is expected to close on or around June 1, 2020 (the “Closing Date”).

Anyone who is interested in participating in the current financing may email the Company at: [email protected]
The Offering is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

The Units will be offered: (i) on a private placement basis in all of the provinces and territories of Canada; (ii) in the United States on a private placement basis in reliance on Rule 506(b) of Regulation D or pursuant to other exemptions from the requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and in compliance with applicable United States federal securities laws and any “blue sky” laws or regulations of any state of the United States; and (iii) in such jurisdictions outside of Canada and the United States as determined by the Company on a private placement or equivalent basis.

Participation in the Offering will be open to anyone who qualifies under an accredited investor exemption and to existing shareholders (each an “Existing Shareholder”) of the Company as of the close of business on May 19, 2020 (the “Record Date”) who are eligible to participate in the Offering in reliance on the existing shareholder exemption under Canadian securities laws (the “Existing Shareholder Exemption”).

The aggregate acquisition cost to an Existing Shareholder relying on the Existing Shareholder Exemption cannot exceed $15,000 in any 12-month period, unless such Existing Shareholder has obtained advice regarding the suitability of the investment from a registered investment dealer in that Existing Shareholder’s jurisdiction. Persons who become shareholders of the Company after the Record Date are not permitted to participate in the Offering using the Existing Shareholder Exemption, however other exemptions may still be available.

The Units and any Warrant Shares issued upon the exercise of the Warrants issued in connection with the Offering will be subject to a statutory hold period in Canada of four months and one day following the Closing Date. Additional resale restrictions may apply under the laws of other jurisdictions.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities described herein have not been and will not be registered under the U.S. Securities Act, or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available.

In addition, the Company has resolved to re-price the 26.9M of currently issued and outstanding common share purchase warrants with exercise prices between $0.30/share and $0.40/share and various expiry dates, to a new reduced exercise price equal to $0.10 per share in order to align with the current proposed private placement and to encourage such warrant holders to exercise their warrants.  This reduction of warrant exercise prices is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

Additional Cost Cutting Measures

As of May 15, 2020, all members of senior management have been asked to agree to a 30% reduction in their cash-based compensation for the next four months, and to instead receive Common Shares in lieu.

The Company wishes to advise shareholders that it has successfully renegotiated approximately CDN$1 million in current payables by its subsidiary into a 24-month payment obligation. The restructuring improves the Company’s balance sheet and reduces monthly cash requirements moving forward. While this alleviates certain cash flow requirements, it does not affect the Company’s need to raise a minimum of $1 million of proceeds under the Offering.

Management Cease Trade Order Update

Additionally, the Company provides the following update on the previously announced management cease trade order (the “MCTO“) issued by the Ontario Securities Commission on March 31, 2020.

The MCTO was issued in connection with the delay by the Company in filing its annual financial statements, management’s discussion and analysis and related officer certifications for the financial year ended November 30, 2019 (collectively, the “Required Filings“) before the prescribed deadline of March 30, 2020.

The Company continues to work closely with its auditor and expects to file the Required Filings before the end of May 2020.

The Company is providing this status update in accordance with National Policy 12- 203 Management Cease Trade Orders (“NP 12-203“). The Company intends to follow the provisions of the Alternative Information Guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases, for as long as the Company remains in default. The Company confirms as of the date of this news release that there has been no material change in the information contained in the default announcement issued on March 13, 2020 and there is no other material information concerning the affairs of the Company that has not been generally disclosed.

Issuance of Common Shares for Services Rendered

The Company has proceeded with the issuance of 472,222 Common Shares, at an issue price of $0.18 per share, to an arm’s length advisor to the Company. The Common Shares, which are subject to a statutory hold period as required by applicable securities laws, are based upon the $85,000 cash value of the services rendered to the Company by the advisor.

About North Bud Farms Inc.

NORTHBUD owns and operates, through its subsidiaries, licensed cannabis facilities in Canada, California and Nevada. Bonfire Brands USA, the Company’s U.S. subsidiary, acquired cannabis production facilities in Salinas, California and Reno, Nevada in late 2019. The Salinas, California 11-acre farm is actively cultivating cannabis in its 60,000 sq. ft. of licensed greenhouse production space. The Reno, Nevada facility, located on 3.2 acres of land, was acquired through the acquisition of Nevada Botanical Science, Inc., and includes a world-class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation space which holds medical and adult-use licenses for cultivation, extraction and distribution. Through its Canadian subsidiary, GrowPros MMP Inc., the Company built and owns a state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada. The Low, Quebec facility currently has 24,500 sq. ft. of licensed indoor cultivation space; the Company has recently submitted its licence amendment application to Health Canada to add an additional 1,000,000 sq. ft. of outdoor cultivation space.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, statements related to the expected proceeds of the Offering, the completion of the Offering including the timing thereof, the intended use of proceeds from the Offering, the timing of the Company filing the Required Filings and the submission of the Company’s license application to Health Canada. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com. 

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

Mota Ventures $MOTA.ca Enters into Binding Term Sheet to Acquire 110,000 Square Foot European Pharmaceutical Manufacturer of Natural Psilocybin Products $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:47 PM on Saturday, May 16th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 16, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) announces that it has entered into a binding term sheet (the Term Sheet“), dated May 14, 2020, with Verrian Ontario Limited (“Verrian“), pursuant to which it proposes to acquire all of the outstanding share capital of Verrian (the “Transaction“). The Term Sheet replaces the previous preliminary letter of intent entered into with Verrian on May 11, 2020. Verrian is an arms’-length privately-held company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.

Verrian will operate three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

“Signing this binding term sheet is an important step towards Mota’s goal of becoming a leader in the natural health space. Verrian’s significant investment into its licensing, research, equipment and facilities have made it one of the top psychedelic medicine companies. Mota is poised to capitalize on an emerging industry and will continue to expand its North American and European operations to ensure a strong distribution network is in place once this line of product is approved to go to market,” stated Ryan Hoggan, CEO of the Company.

The binding Term Sheet contemplates that the Company would acquire all of the outstanding share capital of Verrian in consideration for Cdn$20,000,000, which will be satisfied through the issuance of common shares (the “Consideration Shares“) to the existing shareholders of Verrian. The Consideration Shares will be issued at a deemed price of equivalent to the volume-weighted average closing price of the common shares of the Company in the ten trading days immediately prior to the entering into of definitive documentation in respect of the Transaction.

The Consideration Shares will be subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company will arrange for repayment of existing shareholder loans of Verrian totaling approximately Cdn$1,100,000.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Transaction, an administrative fee of $422,000, payable in common shares of the Company, will be owing to a consultant who assisted with the Transaction.

The Transaction remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approval and the negotiation of definitive documentation, which is expected to include warranties, representations, covenants, terms and conditions which are customary and consistent with industry standards for a transaction of this nature, as a well as a mutual break fee in the event of termination. The Transaction cannot be completed until these conditions have been satisfied.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

The Canadian Securities Exchange has in no way passed upon the merits of the Transaction, and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

People are choosing #cannabis over cocktails because it’s healthier – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:05 PM on Friday, May 15th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

People are choosing cannabis over cocktails because it’s healthier

  • What’s a safer, healthier option to alcohol? That would be cannabis, say 90 per cent of Americans asked about their use of substances last year.
  • The findings seem to reflect that people trying to adopt healthier lifestyles are thinking cannabis could be a better fit than alcohol, suggests an article by Merry Jane.

By Angela Stelmakowich

A healthier lifestyle was among four factors associated with more people consuming weed in 2019 than in 2018. The other three factors include there being less stigma around cannabis, legalization and decriminalization efforts, and pot from legal U.S. states being sold on the black market in states where cannabis is still a no-no.

The National Cannabis Study, released last month by marketing research firm MRI-Simmons, notes the single-year jump in cannabis consumption between 2018 and 2019 was significant. About 22 per cent of surveyed Americans consumed weed at least once in 2019 compared to 16 per cent in 2018. That represents a 38 per cent hike.

Of those who used cannabis in 2019, the survey shows 17 per cent consumed once a month or more, while seven per cent consumed daily.

Cannabis, herbal supplements and vitamins were all up from 2018 to 2019. / Photo: Christopher Furlong/Getty Images Christopher Furlong/Getty Images

While consumption of cannabis, herbal supplements and vitamins were all up from 2018 to 2019, caffeine and alcohol consumption dropped slightly, both by about three per cent.

About 58 per cent of respondents also said that marijuana should be legal, up from 56 per cent in 2018, and almost two-thirds, 64 per cent, over the age of 18 expect marijuana to become legalized in all states within the next five years.

The study used a nationally representative online sample of more than 5,000 respondents.

Source: https://www.thegrowthop.com/cannabis-news/cannabis-continuing-to-mainstream-with-more-americans-using-weed-in-2019

Datametrex Announces Sale of COVID-19 Test Kit to Canadian Mining Company

Posted by AGORACOM-JC at 10:27 AM on Friday, May 15th, 2020
  • Received a purchase order for COVID-19 test kits from a Canadian based mining company with over 4,000 employees in multiple jurisdictions outside of Canada
  • Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of COVID-19 Detection Kits, comprising of 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples
  • Total gross sales amount is approximately $500,000 CDN, excluding shipping

TORONTO, May 15, 2020 — Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce it has received a purchase order for (the “PO”) COVID-19 test kits from a Canadian based mining company with over 4,000 employees in multiple jurisdictions outside of Canada.

Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of COVID-19 Detection Kits, comprising of 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples. The total gross sales amount is approximately $500,000 CDN, excluding shipping. Datametrex anticipates that it will have little or no upfront costs associated with the sale of these test kits. The Company has secured all testing kits, swabs, tubes and the PCR machine from the manufacturer required to fulfill the order. All of the items will be shipped directly from manufacturers to the purchaser at their operating site in Africa.

“Datametrex is honoured to be assisting this Canadian company to protect and safeguard the health and welfare of their employees, local contractors, and the local population. We are proud to be able to help Canadians and companies to reopen businesses around the world and to help people return to work safely. We sincerely wish them and all Canadian companies the best during this pandemic,” says Marshall Gunter, CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

betterU $BTRU.ca restructures Board of Directors to advance the Company’s global efforts $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 10:05 AM on Friday, May 15th, 2020
http://www.smallcapepicenter.com/BTRU%20Square.png
  • Company has augmented the Board of Directors to include international Board of Directors and Board Advisors
  • Joining the Board of Directors is Duncan Cowie, CPA-CA, and as a Principal Advisor to the Board of Directors, Ambassador Vishnu Prakash

OTTAWA, May 15, 2020 — betterU Education Corp. (TSX VENTURE:BTRU) (FRANKFURT:5OGA), (the “Company” or “betterU”) is pleased to announce that as part of the Company’s 2020 restructuring plan the Company has augmented the Board of Directors to include international Board of Directors and Board Advisors. Joining the Board of Directors is Duncan Cowie, CPA-CA, and as a Principal Advisor to the Board of Directors, Ambassador Vishnu Prakash. The new board support will advance the Company’s expertise in the areas of the education marketing, global business development, financial management, M&A, public markets and board governance. The Company will also continue its efforts over the months to come, to add more expertise to support the Board of Directors and Company leadership.  

Board members Praveen Varshney, Robert Kang and Rajeev Dewan have agreed to step down from the board of Directors effective immediately to allow for the restructuring of the new board and advisors to take place. “With the transformation of our business in early 2020, the advancements of our North American B2B SaaS focus and clients, along with our international growth plans, it is time to bring in new leadership and governance that can help transform and advance our global growth. I want to thank the exiting board members for their time and commitment to the company over the years. Both myself and my Board Chairman, Tony Keenan will continue to work at advancing the strength and support our leadership to be successful in 2020 and beyond”, said Brad Loiselle, President and CEO betterU.   

In early 2020 betterU started advancing their innovative B2B Ready-To-Go platform resulting in several new North American clients. While the betterU team continues to advance their automation and AI capabilities to support the scale of international users, the new Board and Special Board Advisors will provide greater insight, financial governance, investor, public support and connections to help accelerate betterU’s global growth in revenues and strategic partnerships.

About Duncan Cowie

Mr. Cowie has over three decades of holding senior executive positions including as the CEO Global Connect-China, the Executive VP and Regional Manager for Transcom Worldwide / NuComm International, the VP and General Manager / Finance of CSA Group, the Sr. VP and CFO Minacs Worldwide, the CFO and VP for The Hospital for Sick Children and the VP Strategic and Business planning Molson Breweries.

Mr. Cowie also has five years of experience building education and training programs. Experienced in corporate development activities including leadership of international business operations, mergers and acquisitions, partnerships and agency structures. Results demonstrated through leadership decision- making, organizational design and people development, and through the design and execution of strategic and tactical plans. Mr. Cowie’s experience spans the globe with a focus on China and Asia, North America and Europe. Delivering creative and innovative teaching approaches built on real-life experiences and solutions for complex business issues.

“betterU is a rare ed-tech that is driven by a passionate team with a global vision and solutions that are starting to take shape. I am excited to join betterU’s Board of Directors to help support and advance their global efforts. I am looking forward to digging deep into the company and helping them grow,” said Duncan Cowie.

About Ambassador Vishnu Prakash, former Envoy to Canada and South Korea

Mr. Prakash is a lawyer (gold medalist) by training and a diplomat by profession, retired as India’s High Commissioner to Canada in November 2016, after over 35 years in the saddle, as an Indian Foreign Service (IFS) officer. Hitherto, he was Ambassador to South Korea, Official Spokesperson of the Ministry of External Affairs and Consul General to Shanghai. He also held various positions at Indian Missions in Tokyo, New York, Moscow, Islamabad, Vladivostok and Cairo. Mr. Prakash did a sabbatical with the ‘Asia Pacific Center for Security Studies’ in Hawaii (USA) in 1996. In 2013, he was conferred an Honorary Doctoral degree in Business Administration by Tongmyong University, Busan (South Korea) and also recognized as the ‘Ambassador of the Year, 2014’ by the Asia Society, Korea Center.

Presently Mr. Prakash is a foreign affairs analyst, speaker, columnist and commentator. His areas of interest span the Indo-Pacific region, including North-east Asia (China, Japan and Koreas), ASEAN & South Asia, the US, Canada and Israel.

Ambassador Prakash is a sought-after speaker, across the country, by colleges, Universities and training institutions especially on Indian diplomacy and international issues. He was recognized as an “Outstanding Diplomat” by PIMR (Prestige Institute of Management and Research), Indore in January 2020.

He has been writing for Hindustan Times, The Korea Times, The Asian Age, ETV Bharat, and The Quint, among other media outlets. Mr. Prakash has been associated with and / or contributing papers / articles for prominent think-tanks like IDSA, Ananta Aspen Centre, ORF, VIF and ICS, to name a few. He has also contributed chapters for publications by IDSA and Indian Foreign Affairs Journal. Amb. Prakash regularly appears as an expert panelist on Indian and international TV channels.

“I have had the opportunity to work with the CEO of betterU for many years and have grown fond of his vision and passion for supporting access to education in my country. I am thrilled to join the Company as a Principle Advisory to the Board of Directors and I will be working closely with all board members and the Company’s leadership to help support their efforts not only in India, but globally as well”, said Ambassador Prakash.

About betterU Education Corp.

betterU is an education-to-employment technology company offering an end-to-end solution leveraging business intelligence to automate skilling, reskilling and upskilling for companies operating on domestic and global scales. If you are looking for support in regards to COVID-19, please visit https://readytogo.betteru.ca/ to download your free COVID-19 Resource Toolkit.

betterU has integrated into its platform the content, technology and support for tailored skills assessments, learning pathways and training modules from 100+ of the world’s leading online education providers. betterU’s eco-system includes detailed job, skill, employer, and educational profiles spanning 3,000+ standardized jobs. betterU’s integrated platform is the most efficient solution to address evolving skilling challenges for employers and employees through the employment lifecycle from entry level to executive. We don’t sell content; we help build better people. 

For more information, please visit https://corporate.betteru.ca/  For more information about betterU’s Enterprise SaaS Program please visit https://readytogo.betteru.ca/

Contact:

Brad Loiselle, CEO
1-613-695-4100

betterU Education Corp.
Investor Relations
Email: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.